Antonio Giovanni Richetta (Antonio G Richetta, Antonio Richetta)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Ejection Fraction

Juvenile Idiopathic Arthritis

Cross Sectional

Top Venues

The Journal of dermatological treatment

Expert opinion on biological therapy

Patient preference and adherence

The Australasian journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Orsini Diego, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio Giovanni Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro Marco Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study). The Journal of dermatological treatment 35 (1) (2024)
Orsini Diego, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio Giovanni Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro Marco Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study). The Journal of dermatological treatment 35 (1) (2024)
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, Andrea Chiricozzi, Clara De Simone, Claudio Bonifati, Pierluigi Bruni, Diotallevi Federico, Maria Esposito, Dario Graceffa, Katharina Hansel, Francesco Loconsole, Gaia Moretta, Cristina Mugheddu, Manuela Papini, Antonio Giovanni Richetta, Nevena Skroza, Laura Atzori, Maria-Concetta Fargnoli, Severino Persechino, Annamaria Offidani, Luca Stingeni, Ketty Peris, Concetta Potenza, Luca Bianchi
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert opinion on biological therapy (2022)
Giuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, Ginevra Baggini, Manuela Baldari, Gianpiero Castelli, Simmaco Coppola, Antonio Costanzo, Rocco De Pasquale, Maria-Concetta Fargnoli, Caterina Foti, Claudia Giofrè, Serena Lembo, Claudia Leporati, Francesco Loconsole, Giovanna Malara, Ketty Peris, Antonio Giovanni Richetta, Paola Savoia, Rossana Tiberio, Massimo Travaglini, Maria Teresa Uzzauto, Luca Bianchi
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. Patient preference and adherence 15 (2021)
Arianna Zangrilli, Giacomo Caldarola, Nicoletta Bernardini, Mauro Bavetta, Dario Graceffa, Claudio Bonifati, Franca Cantoresi, Sara Faleri, Domenico Giordano, Marco Mariani, Adriana Micheli, Gaia Moretta, Federico Pirro, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Giovanni Richetta, Lidia Sacchelli, Luca Bianchi, Ketty Peris
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert opinion on biological therapy 21 (9) (2021)
Antonio Giovanni Richetta, Federica Marraffa, Sara Grassi, Emilia Aquila, Agnieszka Dybala, Francesca Aprile, Manuela Merli
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report. The Australasian journal of dermatology 62 (3) (2021)